 2008 |
|
 May
26 |
Medical Use Patent for the Combination Use of HGF and PGIS
Granted in Europe - Covering Angiogenic Therapy - |
| May
15 |
New Medical-Use Patent for HGF Gene Granted in Europe
- Covering Cardiomyopathy - |
| April
14 |
AnGes MG, Inc. Launched Naglazyme in Japan |
| April
7 |
Medical Use Patent on NF-κB Decoy-Oligo Granted in Europe - Covering Its Use for Atopic Dermatitis |
| March
28 |
AnGes Submits NDA for HGF Gene Therapy |
| March
28 |
AnGes MG, Inc. Receives Approval for Manufacturing and Marketing of Naglazyme |
| February
25 |
Status Updates of NDA application of Naglazyme for the Treatment of Mucopolysaccharidosis VI |
| February
12 |
Supplemental Announcement of Results of Phase II Clinical Trials of NF-κB Decoy Oligodeoxinucleotides on Atopic Dermatitis |
| February
8 |
Announcement of Results of Phase II Clinical Trials of
NF-κB Decoy Oligodeoxynucleotide on Atopic Dermatitis |
| 2007 |
|
| December
10 |
Option Agreement Concluded Between Maruishi Pharmaceutical Co., Ltd.
and AnGes MG, Inc.
- Implementing Exploratory Research on Candidate Compound
for Novel Drug for Treatment of Skin Diseases - |
| November
15 |
Announcement of a Contract Concluded by Three Companies on
R&D of “Drug-Eluting Balloon Catheter” for Prevention of
Vascular Restenosis |
| November
15 |
Announcement of Joint R&D Contract Termination between
Goodman Co., Ltd. and AnGes MG, Inc. |
| November
13 |
AnGes MG, Inc., Signs Licensing Deal with Meyer Pharmaceuticals, LLC - The Development and Marketing of NF-κB Decoy Oligo in North America and Europe- |
| October
29 |
Academic Release of Data from Phase III Clinical Trial of HGF Gene Therapy Conducted in Japan |
| August
31 |
A Research-and-Development Project of GenomIdea Inc.,a Subsidiary of AnGes MG, Inc. is Granted Subsidy from New Energy and Industrial Technology Development Organization - Development of Cancer Therapeutic Agent Using HVJ-E Vector - |
| August
29 |
Basic Patent of HGF Gene Therapy is Granted in Korea |
| August
13 |
AnGes MG, Inc. Submits BLA for Naglazyme in Japan |
| July
11 |
Basic Patent for HVJ-E Granted in Japan: A Patent Covering HVJ-E Vector (Product Patent) |
| July
9 |
Completion of Targeted Number of Patient Enrollment in Phase II Clinical Trial of NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis in Japan |
| June
20 |
Announcement on Acquisition of First-Class Drug Marketing Business License |
| June
14 |
Announcement of Results of Phase III Clinical Trials
of HGF Gene Therapy in Japan |
| June
7 |
Announcement Regarding the Official Designation of Naglazyme as an Orphan Drug |
| February
15 |
Toyobo and GenomIdea Forms Business Alliance
- Product Launch of Master Cell Bank for Drug Manufacturing - |
| February
7 |
New Medical-Use Patent for HGF Gene Granted in Japan - Covering Intractable and Diabetes-related Peripheral Arterial Occlusive Diseases - |
| January
22 |
AnGes MG, Inc. Announces Marketing and Distribution Agreement with BioMarin
Pharmaceutical Inc. for Naglazyme in Japan |
| January
11 |
The Clinical Trial of HGF Plasmid in Japan has Achieved Necessary
Number of Subject Enrollment for Efficacy Analysis |
| January
10 |
New Medical-Use Patent for HGF Gene Granted in Japan - Covering Cardiomyopathy - |
| January
5 |
Vical Initiates Pivotal Phase 3 Trial of Allovectin-7® as First-line Therapy for Metastatic
Melanoma |
 |
|
| 2006 |
|
| November
13 |
Avontec (Germany) Starts Phase IIa Clinical Trials of AVT-01
- Obtaining Approval for Initiation of Clinical Trials in the Field of Asthma in Europe - |
| October 31 |
AnGes MG Launches Phase II Clinical Trials of NF-κB Decoy Oligo in the Treatment of Atopic Dermatitis in Japan |
| October 18 |
Efficacy of Drug Delivery System (DDS) Nanoparticles Supported Nucleic Acid
Medicine for Atopic Dermatitis, Developed by Hosokawa Powder Technology
Research Institute and AnGes MG, Inc. Confirmed in Animal Experiments |
| September 7 |
AnGes MG Submitted the Notification of the Clinical Trial Plan for NF-κB Decoy Oligo
- Phase II Clinical Trials of NF-κB Decoy Oligo for the Treatment of Atopic Dermatitis Commences - |
| June
5 |
AnGes MG, Inc. Announce their Policy for Future Development of HGF Gene Therapy |
| June
5 |
AnGes MG, Inc. Releases the Results of the US Phase II
Clinical Trial with HGF Gene Plasmid for PAD (Peripheral Arterial Disease) |
| June
1 |
Completion of Reexamination of the Basic US Patent on
NFκB Decoy Oligonucleotide
-Decision to Maintain Patent- |
| May
30 |
AnGes MG, Inc. and Vical Inc. Sign Collaborative R&D Agreement for Allovectin-7® as well as Equity Investment Agreement |
| May
26 |
Results of Phase I Clinical Trials of NFκB Decoy Oligo
in the Treatment of Atopic Dermatitis |
| May
24 |
A Japanese Medical-Use Patent is Granted for NFκB Decoy Oligonucleotide
-Covering Treatment for Atopic Dermatitis- |
| May
8 |
Results of the US Phase I Clinical Trials with HGF Gene Plasmid for Ischemic Heart Disease (IHD) |
| April
3 |
AnGes MG, Inc. Announces Newly Establishing a Position of CIPO(Chief Intellectual Property Officer) |
| February
22 |
AnGes MG, Inc. Announced Preliminary Results of the US Phase II Clinical
Trial with HGF Gene Therapy for PAD (Peripheral Arterial Disease) |
| February
3 |
Termination of Joint Development with Seikagaku Corporation |
| January 31 |
Medical-Use Patent for HGF Gene Granted in U.S.
- Covering Cardiomyopathy - |
|
|
